Marburg I polymorphism of factor VII-activating protease and risk of recurrent venous thromboembolism

Thromb Haemost 2006; 95(05): 907-908
DOI: 10.1160/TH06-01-0023

Letters to the Editor

Schattauer GmbH

Berthold Hoppe

¹Institute of Transfusion Medicine, Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin, Berlin, Germany

,

Thomas Dörner

¹Institute of Transfusion Medicine, Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin, Berlin, Germany

,

Holger Kiesewetter

¹Institute of Transfusion Medicine, Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin, Berlin, Germany

,

Abdulgabar Salama

¹Institute of Transfusion Medicine, Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin, Berlin, Germany

References
1 Hoppe B, Tolou F, Radtke H. et al. MarburgI polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism. Blood 2005; 105: 1549-51.
2 van Minkelen R, de Visser MCH, Vos HL. et al. The Marburg I polymorphism of factor seven-activating protease is not associated with venous thrombosis. Blood 2005; 105: 4898.
3 Hoppe B, Heymann GA, Radtke H. et al. Association of Marburg I polymorphism of factor VII-activating protease with venous thromboembolism is limited to idiopathic events. Blood 2005; 105: 4899.
4 Ridker PM, Goldhaber SZ, Danielson E. et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425-34.
5 Gulesserian T, Hron G, Endler G. et al. Marburg I polymorphism of factor VII-activating protease and risk of recurrent venous thromboembolism. Thromb Haemost 2006; 95: 65-7.
6 Prandoni P, Lensing AW, Cogo A. et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
7 Baglin T, Luddington R, Brown K. et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523-6.